Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NuGen Medical Devices Inc V.NGMD

Alternate Symbol(s):  NGMDF

NuGen Medical Devices Inc. is a Canada-based specialty medical device company. The Company is engaged in marketing and selling its InsuJet needle-free injection system designed to improve the lives of millions of diabetics. Its principal business is the research, development and commercialization of needle-free injection devices and systems for the administration of subcutaneous medication. It is developing products using its needle-free delivery technology in several fields including, but not limited to, diabetes, semaglutide, growth and fertility hormone, as well as deoxyribonucleic acid (DNA) and conventional/pediatric vaccines. It is focusing its development efforts on needle free devices in the area of liquid jet delivery through the InsuJet platform. The Company's InsuJet technology platform is based on jet-stream administration of liquid drugs. The Company manufactures and commercializes needle-free injection systems and sells in over 40 countries globally.


TSXV:NGMD - Post by User

Post by lscfaon May 28, 2023 11:17am
172 Views
Post# 35467816

Proposed 1 for 30 rollback

Proposed 1 for 30 rollbackto consider and, if deemed advisable, pass, with or without variation, a special resolution to amend the articles of amalgamation of the Company to consolidate each of the issued and outstanding common shares of the Company by changing a maximum of thirty (30) pre-consolidation common shares of the Company, or such lesser number of pre-consolidation common shares as the directors of the Company in their discretion may determine, into one (1) post-consolidation common share of the Company, as more fully described in the accompanying management information circular dated May 12, 2023 of the Company;
<< Previous
Bullboard Posts
Next >>